News | EP Lab | May 12, 2021

Pulsed Electric Field Focal Ablation Catheter From Galaxy Medical and Japan Life Will Seek FDA Clearance 

Companies create U.S. distribution agreement 

EP lab at the University of Colorado

May 12, 2021 — Galaxy Medical and Japan Lifeline announced an exclusive distribution agreement for the Alpha1 ablation catheter in the United States, developed by Japan Lifeline for use with the Galaxy Centauri Pulsed Electric Field (PEF) System.  Under the terms of the agreement, Galaxy will pursue U.S. regulatory approval for Alpha1 in support of eventual commercialization of the CENTAURI PEF System.

PEF is a new type of ablation technology for use in electrophysiology (EP) procedures. It is also called electroporation, because the field it creates opens pores in the cell walls, leading to cell death. The goal is deliver more controlled lesions with less collateral damage. 

The Alpha1 was engineered to handle the increased electrical demands associated with PEF therapy, without sacrificing the handling, flexibility or feel that physicians expect. It has an 8 French outer diameter, 4 mm platinum ablation tip and a full 180 degrees of bilateral deflection. It was optimized to work with the two major inventions that are unique to the Centauri PEF System:

The proprietary Wave1 waveform reduces muscle stimulation and eliminates microbubbles seen with other PEF ablation products that can cause strokes.
The proprietary Centauri Connect box allows physicians to perform PEF ablation procedures with focal catheters and mapping systems they currently use for routine radiofrequency procedures, saving training time, workflow adjustments and cost.

"We have long sought to bring our outstanding ablation technologies to the U.S. market. In this partnership with Galaxy and their expertise in PEF technology, we aim to be at the forefront of innovation in ablation, bringing new therapies to the millions of people worldwide who suffer from cardiac arrhythmias," said Kei Suzuki, CEO of Japan Lifeline.

"We are thrilled to partner with Japan Lifeline on the first focal PEF system. Over the last several months, Galaxy and Japan Lifeline engineers have collaborated to design Alpha1, allowing PEF energy to target a wide array of arrhythmias," said Jonathan Waldstreicher, M.D., CEO of Galaxy Medical. "We chose to start with a focal approach because 87% of catheter ablations worldwide are performed in this manner, aligning with our mission of democratizing the use of PEF energy.  As we embark on clinical trials with the system, we hope to demonstrate enhanced safety and efficacy as compared to today's standard of care."

Centauri and Alpha1 are investigational devices and not commercially available.

For more information: www.galaxymed.com, www.japanlifeline.com

 

Related Pulsed Electric Field Ablation Technology Content:

Pulsed Field Ablation Successfully Treats Atrial Fibrillation

What is New in Electrophysiology Technologies

Medtronic FDA Trial Evaluates Pulsed Electric Fields to Treat Atrial Fibrillation

VIDEO: Current State of Atrial Fibrillation Ablation Technologies

First-in-human Electroporation Ablation Study Finds Pulsed Electric Fields Can Target Specific Tissue For Atrial Fibrillation

First Patients Treated with Galaxy Medical Centauri Pulsed Electric Field Cardiac Ablation System

Boston Scientific Invests in Pulsed Field Ablation Technology To Improve Atrial Fibrillation Therapy

Pulsed AF Trial Shows Pulsed Field Ablation May be Safer Than Traditional RF Ablations
 

 


Related Content

News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
News | EP Lab

April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...

Home April 21, 2025
Home
News | EP Lab

Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home February 14, 2025
Home
News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...

Home June 25, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
News | EP Lab

January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...

Home January 11, 2024
Home
Subscribe Now